DNTH Dianthus Therapeutics
Dianthus Therapeutics earnings company data as of 4:00 PM ET 11/1
Scheduled
1 period, newest first, nothing reported yet. Each row shows EPS above revenue.
| Period | Date | Metric | Estimate | Actual | Result |
|---|---|---|---|---|---|
| FY2026 Q3 | 4 Nov | EPS | -0.95 | — | — |
| Rev | $388.7K | — | — |
Insider trades
Open-market buys and sales by DNTH's executives, directors and 10% owners in the last 12 months, from their Form 4s
- None no insider bought on the open market
- None no sales outside a trading plan
- $71.2M sold by 8 insiders under 10b5-1 plans
-
Edward Carr Chief Accounting OfficerPlanned sale$2M 20,000 shares at $101.38 100% of stakeTraded Sep 17 Filed Sep 18
-
Simrat Randhawa EVP, Head of R&DPlanned sale$2.5M 23,124 shares at $106.41 85% of stakeTraded Sep 1 Filed Sep 3
-
Simon Read DirectorPlanned sale$327K 2,778 shares at $117.55 100% of stakeTraded Aug 19 Filed Aug 19
-
Anne McGeorge DirectorPlanned sale$845K 7,750 shares at $109.01 100% of stakeTraded Aug 10 Filed Aug 11
-
Adam M Veness SVP, General Counsel and Sec.Planned sale$2.2M 20,000 shares at $110.44 100% of stakeTraded Aug 7–10 Filed Aug 11
-
Simon Read DirectorPlanned sale$304K 2,777 shares at $109.55 100% of stakeTraded Aug 10 Filed Aug 11
-
Marino Garcia CEOPlanned sale$17.9M 166,000 shares at $108.11 72% of stakeTraded Aug 7 Filed Aug 7
-
Ryan Savitz CFOPlanned sale$3.2M 31,249 shares at $101.03 100% of stakeTraded Jul 9 Filed Jul 13
-
Adam M Veness SVP, General Counsel and Sec.Planned sale$2.4M 30,000 shares at $80.80 100% of stakeTraded Jun 17 Filed Jun 18
-
Simrat Randhawa EVP, Head of R&DPlanned sale$2.4M 26,530 shares at $90.62 87% of stakeTraded Jun 1 Filed Jun 2
-
Paula Soteropoulos DirectorPlanned sale$51K 599 shares at $85.47 100% of stakeTraded May 8 Filed May 11
-
Ryan Savitz CFOPlanned sale$739K 8,224 shares at $89.84 100% of stakeTraded Apr 9 Filed Apr 10
-
Ryan Savitz CFOPlanned sale$9.5M 114,367 shares at $83.00 100% of stakeTraded Mar 31 Filed Apr 1
-
Paula Soteropoulos DirectorPlanned sale$48K 599 shares at $80.11 100% of stakeTraded Mar 31 Filed Apr 1
-
Paula Soteropoulos DirectorPlanned sale$2.2M 27,594 shares at $78.05 100% of stakeTraded Mar 24 Filed Mar 26
Also filed in the last 12 months, not counted as buying or selling: 41 option exercises.
SEC filings
Recent issuer filings from EDGAR, 20 shown.
| Filed | Form | Detail | Links |
|---|---|---|---|
| SCHEDULE 13G | — | Filing Doc | |
| SCHEDULE 13G/A | — | Filing Doc | |
| SCHEDULE 13G | — | Filing Doc | |
| SCHEDULE 13G | — | Filing Doc | |
| SCHEDULE 13G/A | — | Filing Doc | |
| 8-K | 2.02,9.01 | Filing Doc | |
| 10-Q | Filing Doc | ||
| SCHEDULE 13G/A | — | Filing Doc | |
| 8-K | 8.01,9.01 | Filing Doc | |
| 8-K | 5.07 | Filing Doc | |
| SCHEDULE 13G/A | — | Filing Doc | |
| SCHEDULE 13G | — | Filing Doc | |
| SCHEDULE 13G/A | — | Filing Doc | |
| SCHEDULE 13G/A | — | Filing Doc | |
| SCHEDULE 13G/A | — | Filing Doc | |
| 8-K | 2.02,9.01 | Filing Doc | |
| 10-Q | Filing Doc | ||
| SCHEDULE 13G | — | Filing Doc | |
| DEF 14A | Filing Doc | ||
| DEFA14A | Filing Doc |
No filings match this filter.
Estimates are consensus figures; SEC filings remain the official record. Not investment advice.
Further reading
As an Amazon Associate, FollowTheFilings earns from qualifying purchases.
- How to Read a Financial Report (Tracy & Tracy) View on Amazon
- Financial Statements QuickStudy Laminated Guide View on Amazon
- Financial Intelligence, Revised Ed. View on Amazon